Cymabay Therapeu Performance

CBAYDelisted Stock  USD 11.83  0.27  2.34%   
The firm shows a Beta (market volatility) of -1.38, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Cymabay Therapeu are expected to decrease by larger amounts. On the other hand, during market turmoil, Cymabay Therapeu is expected to outperform it. Cymabay Therapeu right now shows a risk of 0.0%. Please confirm Cymabay Therapeu downside variance, and the relationship between the sortino ratio and accumulation distribution , to decide if Cymabay Therapeu will be following its price patterns.

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Cymabay Therapeu has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Cymabay Therapeu is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more
Begin Period Cash Flow20.3 M
  

Cymabay Therapeu Relative Risk vs. Return Landscape

If you would invest  1,183  in Cymabay Therapeu on October 11, 2024 and sell it today you would earn a total of  0.00  from holding Cymabay Therapeu or generate 0.0% return on investment over 90 days. Cymabay Therapeu is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Cymabay, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  

Cymabay Therapeu Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Cymabay Therapeu's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cymabay Therapeu, and traders can use it to determine the average amount a Cymabay Therapeu's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.0

Best PortfolioBest Equity
Good Returns
Average Returns
Small Returns
CashSmall RiskAverage RiskHigh RiskHuge Risk
CBAY
Based on monthly moving average Cymabay Therapeu is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cymabay Therapeu by adding Cymabay Therapeu to a well-diversified portfolio.

Cymabay Therapeu Fundamentals Growth

Cymabay Stock prices reflect investors' perceptions of the future prospects and financial health of Cymabay Therapeu, and Cymabay Therapeu fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cymabay Stock performance.

About Cymabay Therapeu Performance

Evaluating Cymabay Therapeu's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Cymabay Therapeu has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cymabay Therapeu has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California. Cymabay Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 59 people.

Things to note about Cymabay Therapeu performance evaluation

Checking the ongoing alerts about Cymabay Therapeu for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cymabay Therapeu help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Cymabay Therapeu is not yet fully synchronised with the market data
Cymabay Therapeu has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 31.07 M. Net Loss for the year was (105.37 M) with loss before overhead, payroll, taxes, and interest of (41.63 M).
Cymabay Therapeu currently holds about 153.42 M in cash with (72.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.81.
Over 99.0% of the company shares are held by institutions such as insurance companies
Evaluating Cymabay Therapeu's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Cymabay Therapeu's stock performance include:
  • Analyzing Cymabay Therapeu's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cymabay Therapeu's stock is overvalued or undervalued compared to its peers.
  • Examining Cymabay Therapeu's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Cymabay Therapeu's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cymabay Therapeu's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Cymabay Therapeu's stock. These opinions can provide insight into Cymabay Therapeu's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Cymabay Therapeu's stock performance is not an exact science, and many factors can impact Cymabay Therapeu's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Other Consideration for investing in Cymabay Stock

If you are still planning to invest in Cymabay Therapeu check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cymabay Therapeu's history and understand the potential risks before investing.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Stocks Directory
Find actively traded stocks across global markets
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges